US Capitol Capsule: Transferable market exclusivity: Antibiotics savior?
This article was originally published in Scrip
Executive Summary
Even though the Generating Antibiotic Incentives Now Act of 2012 provided new incentives, such as an additional five-years of market exclusivity for medicines targeting some of the deadliest infections, like methicillin-resistant Staphylococcus aureus, Klebsiella pneumoniae and Acinetobacter baumannii, those enticements have fallen short of what's needed to get more firms to pursue new anti-infectives, representatives from industry, healthcare professional associations and academic research institutions told lawmakers on 19 September.